Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROBUPHINE vs BUNAVAIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist. Also inhibits norepinephrine and dopamine reuptake.
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that prevents misuse via injection.
Treatment of opioid dependence,Off-label: management of chronic pain,Off-label: treatment of opioid-induced constipation
FDA-approved for the treatment of opioid dependence, including induction and maintenance therapy.
Sublingual: 8 mg to 24 mg once daily initially, then 12-16 mg once daily; maximum 24 mg/day.
For moderate to severe opioid use disorder: sublingual film, induction: 2-4 mg buprenorphine/0.5-1 mg naloxone on day 1, then up to 8 mg/2 mg on day 2; maintenance: target 16 mg/4 mg sublingually once daily, range 4-24 mg/1-6 mg daily.
Terminal elimination half-life: 37 hours (range 24-48 h) due to slow release from tissue binding and enterohepatic recirculation; contributes to prolonged dosing interval (every 4 weeks) and delayed withdrawal onset.
Terminal elimination half-life of buprenorphine is approximately 24-42 hours (mean ~37 hours) due to slow dissociation from mu-opioid receptors, supporting extended dosing intervals.
Primarily metabolized by CYP3A4 and CYP2B6 to norbuprenorphine (active). Glucuronidation via UGT1A1 and UGT2B7.
Buprenorphine is primarily metabolized via N-dealkylation by CYP3A4 to norbuprenorphine; also undergoes glucuronidation. Naloxone undergoes hepatic metabolism primarily by glucuronidation.
Primarily renal (70-80% as unchanged drug and active metabolite norbuprenorphine), biliary/fecal (20-30%)
Fecal (~70%) as unconjugated buprenorphine and metabolites; renal (~30%) primarily as conjugated metabolites.
96% bound to plasma proteins (primarily alpha- and beta-globulins, minor albumin binding)
Approximately 96% bound to alpha- and beta-globulins, not significantly to albumin.
Vd: 2.5-3.0 L/kg; large distribution due to high lipophilicity and extensive tissue binding, indicating slow redistribution.
Vd: 2.5-4.0 L/kg, indicating extensive tissue distribution and high lipophilicity.
Sublingual: 30-50% (due to first-pass metabolism). Transdermal: 15-20% (rate-controlled delivery). Oral: <10% (extensive first-pass) and not clinically used.
Buccal: ~30-40% relative to intravenous; sublingual: ~30% due to first-pass metabolism; buccal route avoids some gastrointestinal degradation.
No dose adjustment required for mild to moderate renal impairment. For severe (Cr Cl <30 m L/min): not recommended.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl < 30 m L/min): use with caution; consider dose reduction or extended intervals due to potential accumulation of buprenorphine.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B): reduce starting dose by 50% and titrate slowly. For mild impairment (Child-Pugh class A): no dose adjustment required.
Weight-based: 0.1-0.2 mg/kg sublingually once daily, titrate up to maximum 0.4 mg/kg/day; maximum 24 mg/day.
Not approved for patients under 16 years; safety and efficacy not established. For adolescents 16 years and older: use adult dosing based on weight and severity.
Start at lower end of dosing range (e.g., 4-8 mg sublingually once daily) with cautious titration due to increased sensitivity and risk of CNS depression.
No specific dose adjustment in elderly; use caution due to increased sensitivity, impaired hepatic/renal function, and risk of falls. Start at low end of dosing range and titrate slowly.
Risk of respiratory depression, especially with concurrent use of CNS depressants or in patients with compromised respiratory function. Risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Potential for life-threatening QT prolongation at high doses.
Risk of addiction, abuse, and misuse; respiratory depression and death with IV administration; neonatal opioid withdrawal syndrome with prolonged use; risk of opioid withdrawal with abrupt discontinuation; risk of hepatitis, hepatic events; precipitation of withdrawal if given to patients dependent on full agonists.
Severe respiratory depression; misuse and abuse potential; neonatal opioid withdrawal syndrome; adrenal insufficiency; hepatotoxicity; QT prolongation; dental decay with sublingual use; opioid withdrawal syndrome with naloxone coadministration.
Respiratory depression; neonatal opioid withdrawal syndrome; hepatic injury; precipitation of opioid withdrawal; risks from concomitant use with benzodiazepines or CNS depressants; dependence and withdrawal; use in patients with compromised respiratory function; increased intracranial pressure; hypotension; biliary tract disease; QT prolongation; impairment of driving/operating machinery.
Hypersensitivity to buprenorphine; severe respiratory depression; acute or severe bronchial asthma; paralytic ileus; use of monoamine oxidase inhibitors within 14 days.
Hypersensitivity to buprenorphine or naloxone; patients with significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; patients not already dependent on opioids (for induction).
No specific food interactions are reported for buprenorphine. However, grapefruit and grapefruit juice may theoretically affect metabolism via CYP3A4 inhibition, altering drug levels. Avoid excessive intake.
No significant food interactions. However, patients should avoid grapefruit juice as it may increase buprenorphine levels. Advise to take on an empty stomach for consistent absorption, though food does not significantly alter bioavailability.
Probupine is classified as FDA Pregnancy Category C. In animal studies, it caused fetal harm (increased resorption, skeletal anomalies) at doses 0.5 times the human dose. There are no adequate human studies. First trimester exposure may be associated with neural tube defects; second and third trimester exposure may cause fetal hydantoin syndrome (craniofacial anomalies, growth retardation, neurodevelopmental delay) and increased risk of hemorrhage due to vitamin K depletion.
Buprenorphine, a component of BUNAVAIL, is not associated with major congenital malformations. However, third-trimester use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Use in pregnancy only if benefit outweighs risk.
Probupine is excreted into breast milk. M/P ratio is approximately 0.45. Infant daily dose is estimated at 1-5% of maternal weight-adjusted dose. Reports of sedation and poor suckling in breastfed infants; cautious use recommended, especially in neonates with UDP-glucuronosyltransferase deficiency.
Buprenorphine is excreted into breast milk in low concentrations; estimated relative infant dose is 2.4% of maternal weight-adjusted dose. M/P ratio is not well established. Caution is advised, monitor for infant sedation and respiratory depression.
Increased hepatic clearance during pregnancy, especially third trimester, necessitating dose increases up to 30-50% to maintain therapeutic levels. Postpartum dose should be reduced to prepregnancy levels within 2 weeks. Monitor trough levels every 2 weeks during pregnancy and adjust accordingly.
Pregnancy may alter buprenorphine pharmacokinetics; dose adjustments may be needed to avoid withdrawal or oversedation. Monitor clinical response and adjust doses in increments of 2-4 mg sublingual buprenorphine as needed, guided by withdrawal symptoms and cravings.
Probupine is not a recognized drug; verify spelling. If referring to buprenorphine, note that it is a partial mu-opioid agonist used for opioid use disorder and pain. Monitor for respiratory depression, especially when combined with CNS depressants. Due to its partial agonist activity, it has a ceiling effect for respiratory depression. High doses may precipitate withdrawal in opioid-dependent patients. Naloxone may not fully reverse buprenorphine effects; consider higher doses or respiratory support.
BUNAVAIL (buprenorphine/naloxone) sublingual film is indicated for maintenance treatment of opioid dependence. Administer as a single daily dose; films can be cut to achieve lower doses. Avoid abrupt discontinuation to prevent withdrawal. Monitor for respiratory depression, especially during induction. Use with caution in patients with hepatic impairment; naloxone component may precipitate withdrawal in opioid-tolerant patients if injected.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,Avoid alcohol, benzodiazepines, and other sedatives unless directed by your physician, as they increase risk of serious side effects.,Do not stop suddenly; withdrawal may occur. Follow a tapering schedule if discontinuing.,Keep out of reach of children and others; misuse can cause addiction, overdose, or death.,Store safely at room temperature, away from moisture and heat.
Place the film under the tongue and allow it to dissolve completely; do not chew, swallow, or move the film after placement.,Do not drink or eat until the film has completely dissolved.,Avoid use of alcohol or other central nervous system depressants (e.g., benzodiazepines) while taking this medication as it may increase risk of respiratory depression.,Do not stop taking this medication suddenly without consulting your healthcare provider as withdrawal symptoms may occur.,Store at room temperature away from moisture and heat; keep out of reach of children.,This medication can cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Inform all healthcare providers that you are taking this medication before any surgery or emergency treatment.,Do not take other opioids, including illicit drugs, while on this medication as it may cause severe withdrawal or overdose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROBUPHINE vs BUNAVAIL, answered by our medical review team.
PROBUPHINE is a Opioid Partial Agonist that works by Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist. Also inhibits norepinephrine and dopamine reuptake.. BUNAVAIL is a Opioid Partial Agonist Combination that works by Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that prevents misuse via injection.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROBUPHINE and BUNAVAIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROBUPHINE is: Sublingual: 8 mg to 24 mg once daily initially, then 12-16 mg once daily; maximum 24 mg/day.. The standard adult dose of BUNAVAIL is: For moderate to severe opioid use disorder: sublingual film, induction: 2-4 mg buprenorphine/0.5-1 mg naloxone on day 1, then up to 8 mg/2 mg on day 2; maintenance: target 16 mg/4 mg sublingually once daily, range 4-24 mg/1-6 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROBUPHINE and BUNAVAIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROBUPHINE is classified as Category C. Probupine is classified as FDA Pregnancy Category C. In animal studies, it caused fetal harm (increased resorption, skeletal anomalies) at doses 0.5 times the human dose. There are. BUNAVAIL is classified as Category C. Buprenorphine, a component of BUNAVAIL, is not associated with major congenital malformations. However, third-trimester use may cause neonatal opioid withdrawal syndrome (NOWS) and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.